• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI EvidencePulse™
  • Pharma
  • AI News
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI EvidencePulse™
  • Pharma
  • AI News
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home AI Roundup

Mental Health Chatbot Woebot Shown to Help with Postpartum Depression and Anxiety

byDeepti Shroff Karhade
May 13, 2025
in AI Roundup
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

Key Points:
1. In a randomized controlled trial, use of Woebot, a mental health chatbot, significantly reduced symptoms of postpartum depression and anxiety compared to waitlist controls.
2. Improvements were observed as early as two weeks into the intervention and sustained at six weeks, with large effect sizes across multiple psychometric scales.

Postpartum depression and anxiety remain underrecognized and undertreated among new mothers, often due to stigma, lack of time, or limited mental health resources. A recent randomized controlled trial (RCT) evaluated the use of Woebot, a smartphone-based chatbot powered by artificial intelligence, to deliver cognitive behavioral therapy (CBT) to postpartum women. The trial enrolled 184 participants within six months of childbirth who screened positive for symptoms using the Edinburgh Postnatal Depression Scale (EPDS) or the Generalized Anxiety Disorder-7 (GAD-7) assessment. Participants were randomly assigned to either a six-week Woebot program or a waitlist control group. The chatbot provided daily CBT-based exercises, emotional support, and conversational check-ins using natural language processing. By week six, participants using Woebot showed significantly greater reductions in both depression and anxiety symptoms. The mean EPDS score dropped by over five points in the intervention group compared to just one point in controls, while GAD-7 scores also improved meaningfully. Over 70 percent of the Woebot users achieved a clinically significant improvement on at least one scale, compared to only 30 percent of those in the control group. The tool was well tolerated, with no adverse events reported and high levels of user satisfaction. Engagement was strong, with participants averaging nearly five interactions per week. Researchers emphasized that Woebot is not a replacement for in-person care but could be an early or supplemental option for those lacking access to therapy. As a scalable, low-cost solution, it could play a key role in expanding postpartum mental health support to underserved populations.

Relevant reading: Woebot chatbot reduces postpartum depression and anxiety in randomized trial

©2025 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

RELATED REPORTS

India opens first Department of Artificial Intelligence in Healthcare

Artificial intelligence matches dermatologists in melanoma diagnosis

Artificial intelligence accelerates drug discovery and reduces animal testing

Tags: anxietyartificial intelligencemental healthpostpartum depression
Previous Post

AI Symptom-Checker Could Help Emergency Doctors Prioritize Patients

Next Post

FDA Approves Dupilumab for Chronic Spontaneous Urticaria

RelatedReports

Downward trend in mortality rate for antineutrophil cytoplasmic autoantibody-associated vasculitis
AI Roundup

India opens first Department of Artificial Intelligence in Healthcare

September 17, 2025
Patient Basics: Melanoma
AI Roundup

Artificial intelligence matches dermatologists in melanoma diagnosis

September 15, 2025
Variation noted across pre- and post-marketing studies for FDA approved devices
AI Roundup

Artificial intelligence accelerates drug discovery and reduces animal testing

September 12, 2025
No obesity paradox found between BMI, stroke, and death
2 Minute Medicine

Natural language processing (NLP) model sped up patient message management in the electronic health record (EHR)

September 9, 2025
Next Post
Combined immunotherapy may improve survival in metastatic pancreatic cancer

FDA Approves Dupilumab for Chronic Spontaneous Urticaria

Biosimilar to infliximab shows equivalent safety and efficacy for treating Crohn’s disease

Both intestinal ultrasound and magnetic resonance imaging can assess radiologic stricturing in Crohn's disease

Food environment associated with gestational diabetes

Eli Lilly Takes Legal Action Against Telehealth Startups

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Digital Psychological Intervention for Inflammatory Rheumatic Diseases: A Pilot Randomized Clinical Trial
  • FDA escalates warning letters over misleading drug advertising
  • Therapeutic Effectiveness and Safety Profiles of Medications for Migraine
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2025 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI EvidencePulse™
  • Pharma
  • AI News
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2025 2 Minute Medicine, Inc. - Physician-written medical news.